MIAMI, FL– May 8, 2024 – This week, Epione will celebrate another milestone at a leading cancer institute where the 100th patient will be treated using the technology. Epione, a robotic-assisted platform used in interventional oncology, is designed to support physicians during minimally invasive, percutaneous ablations of abdominal tumors.
“Many patients cannot undergo extensive surgery, or their tumors are considered inoperable for various reasons, and image-guided ablation is a minimally invasive treatment option for them,” shared Dr. Govindarajan Narayanan, Chief of Interventional Oncology with Miami Cancer Institute and Miami Cardiac & Vascular Institute, part of Baptist Health South Florida. “Robotic-assisted ablations allow physicians to plan and place the ablation probe with precision and obtain post-procedure confirmation of ablation success while reducing the radiation exposure to the patient and the physician.”
A minimally invasive procedure, Epione uses CT-guided navigation for the percutaneous ablation of tumors in the abdomen. A robotic arm guides physicians to the best entry point, allowing them to precisely insert a needle while avoiding critical structures. Because physicians can quickly perform these procedures, patients may be able to go home the same day.
“Our mission has been to develop state-of-the-art technology that has the potential to help physicians improve the lives of patients diagnosed with cancer,” said Bertin Nahum, CEO and co-founder of Quantum Surgical. “With yet another significant milestone, Epione has proved its relevance for interventional oncology. We aim to expand the availability of less invasive treatments for a greater number of patients.”
About Quantum Surgical
Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida. Its Epione® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.
Press contact Quantum Surgical
Stéphanie Moy
s.moy@quantumsurgical.com
Tel. : +33 (0)6 32 55 85 48
